Compare SDOT & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDOT | ENSC |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.3M |
| IPO Year | 2020 | N/A |
| Metric | SDOT | ENSC |
|---|---|---|
| Price | $3.26 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.0K | ★ 82.3K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $467,078,000.00 | $4,487,973.00 |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.51 |
| 52 Week Low | $2.43 | $1.46 |
| 52 Week High | $43.90 | $10.96 |
| Indicator | SDOT | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 36.37 |
| Support Level | $2.74 | $1.46 |
| Resistance Level | $3.37 | $1.85 |
| Average True Range (ATR) | 0.37 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 30.15 | 26.95 |
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.